Larvol Delta - The-application-of-rituximab-during-the-conditioning-regimen-prevents-Epstein--Barr-virus-infection-following-rATGbased-haploidentical-hematopoietic-stem-cell-transplantation-in-the-era-of-letermovir-for-cytomegalovirus-prophylaxis

Rituxan (rituximab) - Roche

Thymoglobulin (anti-thymocyte globulin (rabbit)) - Sanofi

Prevymis (letermovir) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42404888

Jinxia Hao; Juan Ren; Tongxin Zhang; Xiaoning Wang

Jul 7, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next